Dr Biljana Stankovic completed her undergraduate studies at the Faculty of Biology, University of Belgrade, Department of Molecular Biology and Physiology. She earned her PhD in 2015 at the Faculty of Biology, University of Belgrade, with a dissertation titled “Molecular Markers of Chronic Inflammation and Apoptosis in Inflammatory Bowel Diseases.” In 2021, she completed the program “Bioinformatics for Biologists” at the Faculty of Computer Science, Union University in Belgrade. She has been employed at the IMGGE since 2010 and is currently a member of the Group for Molecular Biomedicine. Throughout her career, she has focused on researching the molecular basis of inflammatory diseases as well as the pharmacogenetics of anti-inflammatory and immunomodulatory drugs. Her current scientific work is centered on large-scale genomic data analysis, including conducting genome-wide association studies, analyzing polygenic risk scores, and developing predictive models based on machine learning to forecast complex biological phenotypes. She has participated in numerous national and international research projects. She is currently the work package leader on the Horizon Europe project InnoThyroGen, which aims to create innovative digital solutions for advancing genomics-based medicine in the field of thyroid diseases. She also serves as Vice-Chair of the COST Action INFLAMomx, which focuses on systematizing and advancing knowledge in the integration of multi-omics data related to inflammation- and age-associated diseases. Dr. Stanković was a member of the Organizing and Program committees of the Belgrade Bioinformatics Conference (2018, 2024). She actively contributes to the organization of summer schools, workshops, and courses dedicated to the application of bioinformatics and pharmacogenetics in biomedical research.